https://www.selleckchem.com/pr....oducts/trastuzumab-d
3, 80.6, 61.1 and 213.8 mg g-1, respectively. Cyclic tests also confirmed a relatively strong stability for the as-synthesised adsorbents. PURPOSE To predict clinically significant prostate cancer (cs-PCa) by combining the Prostate Imaging Reporting and Data System version 2 (PI-RADS v2) score based on biparametric magnetic resonance imaging (bp-MRI) and clinical indicators in men with prostate-specific antigen (PSA) levels in the gray zone of 4-10 ng/mL. METHOD We retrospectively analyzed 364 patients with elevated PSA l
Like
Comment
Share
